---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-004927"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2024-02-05T23:59:59+00:00"
generated_at: "2026-06-06T09:13:37.781718+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharma acquires PSMA-Boron theranostic asset; engages new IR firm

## Summary
- Upfront $10k each and milestone payments up to $40k each to inventors; 3% royalty on net revenues.
- PSMA-Boron is a theranostic agent for diagnosis, staging, and therapy of prostate cancer.
- Company engaged John Columbia Inc. to supplement existing IR firm Lytham Partners.
- Asset purchase agreement executed Jan 30, 2024; inventors assigned all rights to company.

## SEC filing metadata
- accession: 0001493152-24-004927
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2024-02-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315224004927/0001493152-24-004927-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315224004927/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-004927
- JSON: https://secwatch.observer/filing/0001493152-24-004927.json
- Plain text: https://secwatch.observer/filing/0001493152-24-004927.txt

## Key facts
- Material Agreements
  Shuttle Pharmaceuticals Holdings, Inc. entered into Asset Purchase Agreement with Alan Kozikowski and Werner Tueckmantel valued at Payment of $10,000 each upon signing; additional payments of $10,000 each upon receipt of a research (effective 2024-01-30).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Alan Kozikowski and Werner Tueckmantel
  - Value: Payment of $10,000 each upon signing; additional payments of $10,000 each upon receipt of a research
  - Effective: 2024-01-30
  source text: On January 30, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an asset purchase agreement (the “Asset Purchase Agreement”) and an Assignment of Invention Agreement (the “Assignment”) with Alan Kozikowksi and Werner Tueckmantel (together, the “Inventors”) pursuant to which the Inventors assigned all of their rights, title and interest in the invention entitled “PSMA-Boron” (the “Invention”) to the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757499/000149315224004927/0001493152-24-004927-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.